Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.70 |
| ▸ | BRD2 | P25440 | 4/20 | 0.70 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.70 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.70 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19129434 | 0.99 | BRD4 (0.70) | BRD4BRD2BRD3BRDTMAOB | |
| SCHEMBL17185525 | 0.93 | BRD4 (0.78) | BRD4BRD2BRD3BRDTMAOB | |
| SCHEMBL17185540 | 0.92 | BRD4 (0.77) | BRD4BRD2BRD3BRDTMAOB | |
| SCHEMBL19129435 | 0.85 | MAOB (0.61) | BRD4BRD2BRD3BRDTMAOB | |
| SCHEMBL19129535 | 0.84 | ACHE (0.63) | MAOBMAOAABCB1 | |
| SCHEMBL19129478 | 0.83 | ACHE (0.64) | MAOBMAOAABCB1 | |
| SCHEMBL19129744 | 0.83 | MAOB (0.58) | BRD4BRD2BRD3BRDTMAOB | |
| SCHEMBL23787098 | 0.82 | BRD4 (1.00) | BRD4BRD2BRD3BRDTKDM4E | |
| SCHEMBL20271950 | 0.82 | BRD4 (1.00) | BRD4BRD2BRD3BRDTKDM4E | |
| SCHEMBL20271946 | 0.81 | BRD4 (1.00) | BRD4BRD2BRD3BRDTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868715-B2 | Apigenin analogs, compositions, and methods related thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | CBS, CTH, PTGIS | BRD4 1611/4885BRD2 1963/4885BRD3 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.